Assembly Biosciences, Inc. (ASMB) financial statements (2020 and earlier)

Company profile

Business Address 331 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments274218120536829
Cash and cash equivalents474182292729
Short-term investments227177382441 
Receivables322   
Other current assets    10
Other undisclosed current assets5211  
Total current assets:283223123546829
Noncurrent Assets
Operating lease, right-of-use asset12
Property, plant and equipment211000
Long-term investments and receivables  3223 
Long-term investments  3223 
Intangible assets, net (including goodwill)424242424242
Goodwill131313131313
Intangible assets, net (excluding goodwill)292929292929
Other noncurrent assets23    
Other undisclosed noncurrent assets  0000
Total noncurrent assets:574646456542
TOTAL ASSETS:3402681699813471
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10106520
Accounts payable2     
Accrued liabilities8106520
Deferred revenue6
Debt3     
Deferred revenue and credits5   
Deferred tax liabilities3   12
Other undisclosed current liabilities56221(11)
Total current liabilities:241813731
Noncurrent Liabilities
Long-term debt and lease obligation9     
Operating lease, liability9
Liabilities, other than long-term debt33041   
Deferred revenue and credits41   
Deferred revenue31
Deferred rent credit 0
Deferred income tax liabilities3
Other undisclosed noncurrent liabilities 392111212
Total noncurrent liabilities:423943111212
Total liabilities:675756181513
Stockholders' equity
Stockholders' equity attributable to parent2732111138011959
Common stock000000
Additional paid in capital713553365289284194
Accumulated other comprehensive loss(0)(0)(0)(1)(1) 
Accumulated deficit(439)(342)(251)(208)(164)(136)
Total stockholders' equity:2732111138011959
TOTAL LIABILITIES AND EQUITY:3402681699813471

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues16159   
Revenue, net9   
Cost of revenue
(Cost of Goods and Services Sold)
  (5)   
Gross profit:16154   
Operating expenses(119)(108)(61)(45)(30)(37)
Other undisclosed operating income  5  13
Operating loss:(103)(93)(52)(45)(30)(24)
Nonoperating income430010
Investment income, nonoperating 000(1) 
Loss from continuing operations before income taxes:(98)(90)(52)(45)(28)(24)
Income tax expense (benefit)1(1)91  
Net loss available to common stockholders, diluted:(98)(91)(43)(44)(28)(24)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(98)(91)(43)(44)(28)(24)
Other comprehensive loss  (0)(0)  
Comprehensive loss:(98)(91)(43)(45)(28)(24)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0001(1) 
Comprehensive loss, net of tax, attributable to parent:(97)(91)(43)(44)(29)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: